Development of molecular targeted therapeutics and its biomarkers in endometrial and ovarian clear cell carcinomas

点击翻译按钮获取中文摘要

We elucidated a novel molecular targeted therapeutics and its predictive biomarkers in endometrial and ovarian clear cell adenocarcinomas, on basis of the aberrant signaling pathways in these cancers.1. We found that a PI3K pathway inhibitor (dual PI3K/mTOR inhibitor) is effective in endometrial and ovarian clear cell adenocarcinomas. Furthermore, mutational status of KRAS and TP53 was indicated as predictive biomarkers to the PI3K/mTOR inhibitor.2. We revealed that genome-wide analyses, including single nucleotide polymorphism arrays, are useful for both diagnosis and prediction of prognosis in synchronous endometrial and ovarian carcinomas. In addition, we reported that activation of cyclin D1 and disruption of DNA repair pathways play important roles in endometrial cancer.